A clinician nudge for referral to a gynecologic oncologist at the time of suspected ovarian cancer diagnosis improved referral rates by 20 percentage points, according to study results.Nearly a third ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

Results from the NRG Oncology GOG-0263 Phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...

Moore, MD, discusses the exciting advancements in endometrial cancer treatment, particularly over the past 2 years, as she ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment paradigms in ovarian cancer.

A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in ...

today announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC in an oral presentation at the Society of Gynecologic Oncology (SGO ...

today announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC in an oral presentation at the Society of Gynecologic Oncology (SGO) 2025 ...